100 Or More Amino Acid Residues In The Peptide Chain Patents (Class 514/21.2)
  • Patent number: 10407512
    Abstract: Bi-specific fusion proteins with therapeutic uses are provided, as well as pharmaceutical compositions comprising such fusion proteins, and methods for using such fusion proteins to repair or regenerate damaged or diseased tissue. The bi-specific fusion proteins generally comprise: (a) a targeting polypeptide domain that binds to a target molecule; and (b) an activator domain that detectably modulates tissue regeneration.
    Type: Grant
    Filed: June 9, 2017
    Date of Patent: September 10, 2019
    Assignee: Silver Creek Pharmaceuticals, Inc.
    Inventors: Ulrik Nielsen, Thomas Wickham, Birgit Schoeberl, Brian Harms, Bryan Linggi, Matthew Onsum, Byron DeLaBarre, Shaun M. Lippow
  • Patent number: 10265401
    Abstract: The present invention relates generally to stable formulations comprising CTLA4Ig molecules, including lyophilized, and liquid formulations for administration via various routes including, for example, routes such as intravenous (IV) and subcutaneous (SC) for treating immune system diseases and tolerance induction.
    Type: Grant
    Filed: March 10, 2016
    Date of Patent: April 23, 2019
    Assignee: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Manisha P Desai, Charles E Dahlheim, Sunita Borsadia, Vijay H Naringrekar, Rajesh Babulal Gandhi, Manoj Nerurkar
  • Patent number: 10189881
    Abstract: This disclosure provides an isolated polypeptide comprising no more than 35 amino acids, wherein the amino acid sequence comprises, or alternatively consists essentially of, or alternatively consisting of XXXRYSYXXSYX (SEQ ID NO: 1) and equivalents thereof, wherein X is a basic amino acid and Y is a hydrophobic amino acid. Polynucleotides encoding the polypeptides and antibodies that bind to the polypeptides are also provided. Therapeutic and diagnostic uses are further provided.
    Type: Grant
    Filed: July 25, 2014
    Date of Patent: January 29, 2019
    Assignee: The Regents of the University of California
    Inventors: Reen Wu, Ching-Hsien Chen
  • Patent number: 10166183
    Abstract: The present invention relates to new extended release pharmaceutical compositions and methods of use thereof for the treatment of disorders. In certain embodiments, disclosed herein is an extended-release pharmaceutical formulation comprising, in a solid dosage form for oral delivery of between about 100 mg and about 1 g total weight: between about 2 and about 18% of an active ingredient; between about 70% and about 96% of one or more diluents; between about 1% and about 10% of a water-soluble binder and between about 0.5 and about 2% of a surfactant.
    Type: Grant
    Filed: February 5, 2015
    Date of Patent: January 1, 2019
    Assignee: Auspex Pharmaceuticals, Inc.
    Inventors: Andreas Sommer, Chengzhi Zhang, John Carter, John Arthur, Margaret Bradbury
  • Patent number: 10059960
    Abstract: Compositions and methods for conferring lepidoptericidal activity to bacteria, plants, plant cells, tissues and seeds are provided. Compositions comprising a coding sequence for the Axmi222z toxin polypeptide are provided. The Axmi222z coding sequences can be used in DNA constructs or expression cassettes for transformation and expression in plants and bacteria. Compositions also comprise transformed bacteria, plants, plant cells, tissues, and seeds. In particular, isolated Axmi222z toxin nucleic acid molecules are provided. Additionally, amino acid sequences corresponding to the Axmi222z polynucleotides are encompassed, and antibodies specifically binding to those amino acid sequences. In particular, the present invention provides for isolated nucleic acid molecules comprising nucleotide sequences encoding the amino acid sequence shown in SEQ ID NO:24-26, or the nucleotide sequence set forth in SEQ ID NO:2, 7, 12, and 17, as well as variants and fragments thereof.
    Type: Grant
    Filed: November 4, 2015
    Date of Patent: August 28, 2018
    Assignee: Athenix Corp.
    Inventors: Kimberly Sampson, Daniel Tomso
  • Patent number: 10052360
    Abstract: The present invention relates to compositions and methods for treating autoimmune diseases by administering to a subject a CTLA4 molecule that block endogenous B7 molecules from binding their ligands.
    Type: Grant
    Filed: February 19, 2016
    Date of Patent: August 21, 2018
    Assignee: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Robert Cohen, Suzette Belder-Carr, David Hagerty, Robert James Peach, Jean-Claude Becker
  • Patent number: 9969785
    Abstract: The present disclosure provides compositions and methods for treating diseases or conditions associated with an abnormal level or activity of biglycan; disorders associated with an unstable cytoplasmic membrane, for example, due to an unstable dystrophin associated protein complex (DAPC); disorders associated with abnormal synapses or neuromuscular junctions, including those resulting from an abnormal MuSK activation or acetylcholine receptor (AChR) aggregation. Examples of diseases include muscular dystrophies, such as Duchenne's Muscular Dystrophy, Becker's Muscular Dystrophy, neuromuscular disorders and neurological disorders.
    Type: Grant
    Filed: May 17, 2011
    Date of Patent: May 15, 2018
    Assignee: Brown University
    Inventors: Justin R. Fallon, Alison R. Amenta, Beth A. McKechnie, Michelle Dechene, Atilgan Yilmaz
  • Patent number: 9909140
    Abstract: Compositions and methods for conferring insecticidal activity to host cells are provided. Compositions comprising a coding sequence for a delta-endotoxin polypeptide are provided. The coding sequences can be used in DNA constructs or expression cassettes for transformation and expression in host cells. Compositions also comprise transformed host cells. In particular, isolated delta-endotoxin nucleic acid molecules are provided. Additionally, amino acid sequences corresponding to the polynucleotides are encompassed, and antibodies specifically binding to those amino acid sequences. In particular, the present invention provides for isolated nucleic acid molecules comprising nucleotide sequences encoding the amino acid sequence shown in SEQ ID NO:4, 5, 6, 13, or 14, or the nucleotide sequence set forth in SEQ ID NO:1, 2, 3, 11, or 12, as well as variants and fragments thereof.
    Type: Grant
    Filed: June 8, 2015
    Date of Patent: March 6, 2018
    Assignee: ATHENIX CORP.
    Inventors: Kimberly S. Sampson, Daniel J. Tomso, Shruti Agarwal, Brian McNulty, Chris Campbell
  • Patent number: 9895394
    Abstract: The present invention provides a method for inducing chronic elevation of intraocular pressure in the eyes of an animal by introducing into the eyes a cross-linking hydrogel, an animal produced by this method, as well as a screening method useful for identifying compounds capable of modulating intraocular pressure as well as for identifying compounds capable of modulating retinal ganglion cell survival and/or regeneration.
    Type: Grant
    Filed: March 10, 2015
    Date of Patent: February 20, 2018
    Inventors: Kai-shun Christopher Leung, Ying Chau, Yu Yu
  • Patent number: 9895418
    Abstract: Methods of treating peripheral vascular disease comprising administering a protein solution site of a defect at least two proteins from the group IL-1ra, sTNF-RI, sTNF-RII, IGF-I, EGF, HGF, PDGF-AB, PDGF-BB, VEGF, TGF-?1, and sIL-1RII. The solution may also comprise white blood cells, platelets, concentrated bone marrow aspirate, and combinations thereof.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: February 20, 2018
    Assignee: Biomet Biologics, LLC
    Inventors: Matthew D. Landrigan, Krista O'Shaughnessey, Jennifer E. Woodell-May, David L. Suter
  • Patent number: 9884902
    Abstract: Variants of cytotoxic T-lymphocyte antigen 4 (CTLA-4) with high affinity, potency and stability. Formulations of CTLA-4 variants at high concentration for subcutaneous or intravenous administration, e.g. at monthly or less frequent dosage intervals. Use of CTLA-4 variants for treating rheumatoid arthritis and other inflammatory disorders. Fusion of CTLA-4 with IgG Fc having improved stability and longer in vivo half-life.
    Type: Grant
    Filed: March 11, 2013
    Date of Patent: February 6, 2018
    Assignee: MedImmune Limited
    Inventors: Ralph Minter, Julie Douthwaite, Jacques Moisan, Michael Bowen, Steven Rust, Cyril Privezentzev
  • Patent number: 9877926
    Abstract: A bioadhesive formulation, comprising gelatin, alginate and a coupling agent, capable of forming a bioadhesive matrix, which is characterized by rapid curing, optimal viscosity, high bonding strength, flexibility, biocompatibility and biodegradability, is disclosed. Further disclosed is such a bioadhesive formulation which further comprises a bioactive agent, and a drug-eluting bioadhesive matrix formed therefrom, the bioadhesive matrix being capable of delivering the bioactive agent to a bodily site. Methods utilizing the bioadhesive formulations and matrices in various biological and medical procedures are also disclosed.
    Type: Grant
    Filed: February 14, 2013
    Date of Patent: January 30, 2018
    Assignee: Technology Innovation Momentum Fund (Israel) Limited Partnership
    Inventors: Meital Zilberman, Adaya Shefy-Peleg, Binyamin Cohen, Maytal Foox
  • Patent number: 9850306
    Abstract: The present invention is based on the seminal discovery that targeted immunomodulatory antibodies and fusion proteins can counter act or reverse immune tolerance of cancer cells. Cancer cells are able to escape elimination by chemotherapeutic agents or tumor-targeted antibodies via specific immunosuppressive mechanisms in the tumor microenvironment and such ability of cancer cells is recognized as immune tolerance. Such immunosuppressive mechanisms include immunosuppressive cytokines (for example, Transforming growth factor beta (TGF-?)) and regulatory T cells and/or immunosuppressive myeloid dendritic cells (DCs). By counteracting tumor-induced immune tolerance, the present invention provides effective compositions and methods for cancer treatment, optional in combination with another existing cancer treatment.
    Type: Grant
    Filed: August 8, 2016
    Date of Patent: December 26, 2017
    Assignee: The Johns Hopkins University
    Inventors: Atul Bedi, Rajani Ravi
  • Patent number: 9688666
    Abstract: The present disclosure relates to novel crystalline salt forms of lamivudine, methods for the preparation thereof, pharmaceutical compositions thereof, and their use in the treatment of viruses such as Human Immunodeficiency Virus (HIV) infection.
    Type: Grant
    Filed: February 6, 2014
    Date of Patent: June 27, 2017
    Assignee: TOBIRA THERAPEUTICS, INC.
    Inventors: Sean Mark Dalziel, Mark Michael Menning
  • Patent number: 9587007
    Abstract: The present disclosure relates to CTLA4 proteins and uses of such proteins, for example to treat diseases associated with the dysregulation of immune responses.
    Type: Grant
    Filed: October 27, 2014
    Date of Patent: March 7, 2017
    Assignee: AbbVie Biotherapeutics Inc.
    Inventors: Yoshiko Akamatsu, Veronica Juan, Robert B. Dubridge
  • Patent number: 9572863
    Abstract: The present disclosure relates to methods of treating, ameliorating or preventing a disorder comprising administering a therapeutically effective amount of a composition comprising a protein which inhibits IL-4 and/or IL-13 from binding to their respective receptors to a subject in need thereof. In some embodiments, the disorder is preferably associated with an increase of the Th2 immune response. In some embodiments, administration is preferably locally to the lung in order to treat, ameliorate or prevent allergic asthma, rhinitis, conjunctivitis, lung fibrosis, cystic fibrosis, chronic obstructive pulmonary disease, pulmonary alveolar proteinosis or adult respiratory distress syndrome.
    Type: Grant
    Filed: December 12, 2012
    Date of Patent: February 21, 2017
    Assignee: Pieris Pharmaceuticals GmbH
    Inventors: Andreas Hohlbaum, Laurent Audoly, Beverly Koller
  • Patent number: 9528122
    Abstract: Compositions and methods for conferring pesticidal activity to bacteria, plants, plant cells, tissues and seeds are provided. Compositions comprising a coding sequence for a toxin polypeptide are provided. The coding sequences can be used in DNA constructs or expression cassettes for transformation and expression in plants and bacteria. Compositions also comprise transformed bacteria, plants, plant cells, tissues, and seeds. In particular, isolated toxin nucleic acid molecules are provided. Additionally, amino acid sequences corresponding to the polynucleotides are encompassed, and antibodies specifically binding to those amino acid sequences. In particular, the present invention provides for isolated nucleic acid molecules comprising nucleotide sequences encoding the amino acid sequence shown in SEQ ID NO:3-5, or the nucleotide sequence set forth in SEQ ID NO:2, as well as variants and fragments thereof.
    Type: Grant
    Filed: July 27, 2012
    Date of Patent: December 27, 2016
    Assignee: Athenix Corp.
    Inventors: Kimberly S Sampson, Duane A Lehtinen
  • Patent number: 9518127
    Abstract: The invention relates to inhibitory anti-factor XII/FXIIa antibodies and methods of their use.
    Type: Grant
    Filed: July 20, 2012
    Date of Patent: December 13, 2016
    Assignees: CSL Behring GmbH, CSL Ltd.
    Inventors: Con Panousis, Veronika Rayzman, Andrew Nash, Michael Wilson, Stefan Schmidbauer, Marc Nolte
  • Patent number: 9512215
    Abstract: The invention relates to a stable, pharmaceutically acceptable, aqueous formulation of TNF-binding protein, comprising a TNF-binding protein, a buffer and an isotonicity agent.
    Type: Grant
    Filed: December 15, 2014
    Date of Patent: December 6, 2016
    Assignee: ARES TRADING S.A.
    Inventors: Fabrizio Samaritani, Alessandra Del Rio, Rita Agostinetto
  • Patent number: 9500641
    Abstract: Compositions and methods for altering cell activity and function by expressing a light-activated ion pump polypeptide in a cell and contacting the cell with light that activates the expressed light-activated ion pump polypeptide. In some aspects of the invention, a light-activated ion pump polypeptide is a modified haloarcula halorhodopsin polypeptide, for example, a modified Halo 57 polypeptide.
    Type: Grant
    Filed: January 20, 2015
    Date of Patent: November 22, 2016
    Assignee: Massachusetts Institute of Technology
    Inventors: Amy Chuong, Nathan Klapoetke, Brian Yichiun Chow, Edward Boyden, Xue Han
  • Patent number: 9441231
    Abstract: The present invention provides regulatory polynucleotide molecules isolated from plant proline rich protein genes and linked to a viral enhancer molecule. The invention further discloses compositions, polynucleotide constructs, transformed host cells, transgenic plants and seeds containing the regulatory polynucleotide sequences, and methods for preparing and using the same.
    Type: Grant
    Filed: December 5, 2008
    Date of Patent: September 13, 2016
    Assignee: Monsanto Technology LLC
    Inventors: Stanislaw Flasinski, Shirley Xiaoli Guo, Wei Wu
  • Patent number: 9328154
    Abstract: The present invention provides therapeutic agents and compositions comprising elastic peptides and therapeutic proteins. Such peptides exhibit a flexible, extended conformation. In some embodiments, the therapeutic protein is a GLP-1 receptor agonist (e.g., GLP-1, exendin), insulin, or Factor VII/VIIa, including functional analogs. The present invention further provides encoding polynucleotides, as well as methods of making and using the therapeutic agents. The therapeutic agents have improvements in relation to their use as therapeutics, including, inter alia, one or more of half-life, clearance and/or persistance in the body, solubility, and bioavailability.
    Type: Grant
    Filed: April 16, 2014
    Date of Patent: May 3, 2016
    Assignee: DUKE UNIVERSITY
    Inventor: Ashutosh Chilkoti
  • Patent number: 9314510
    Abstract: The present invention relates to human laminin ?2 chain LG3 domain and active peptides promoting cell adhesion, spreading, migration, and neurite outgrowth. More particularly, it was found that when nerve cells are incubated using human laminin ?2 chain LG3 domain and active peptides in the LG3 domain, cell adhesion, spreading, migration, and neurite outgrowth of nerve cells promote and the promotion of cell adhesion, spreading, migration, and neurite outgrowth of nerve cells are integrin-mediated and achieved by the activation of PKC? and FAK phosphorylation. Thus, the present invention can be very useful for researches on cell adhesion, spreading, migration, and neurite outgrowth activities of cells which are focused on nerve cells and mediated by various extracellular matrix proteins including laminin, manufacture of artificial nerve conduits, burns treatment, wounds treatment, and tissue regeneration.
    Type: Grant
    Filed: March 12, 2012
    Date of Patent: April 19, 2016
    Assignee: SNU R&DB Foundation
    Inventor: Byung-Moo Min
  • Patent number: 9302002
    Abstract: The invention provides stabilized aqueous pharmaceutical etanercept compositions suitable for long-term storage of etanercept, methods of manufacture of these compositions, methods of administration, and kits containing same.
    Type: Grant
    Filed: October 18, 2012
    Date of Patent: April 5, 2016
    Assignee: Coherus Biosciences, Inc.
    Inventors: Mark Manning, Brian Murphy
  • Patent number: 9175045
    Abstract: Biologically active crosslinked polypeptides with improved properties relative to their corresponding precursor polypeptides, having good cell penetration properties and reduced binding to human proteins; and methods of identifying and making such improved polypeptides.
    Type: Grant
    Filed: August 2, 2013
    Date of Patent: November 3, 2015
    Assignee: Aileron Therapeutics, Inc.
    Inventors: Huw M. Nash, David Allen Annis, Rosanna Kapeller-Libermann, Tomi K. Sawyer, Noriyuki Kawahata
  • Patent number: 9138463
    Abstract: The present invention relates to compositions for delivering carbon monoxide (CO) to cells using heme proteins as carriers. In one embodiment, the present invention relates to the use of MalPEG surface modified hemoglobin to deliver CO to cells.
    Type: Grant
    Filed: October 19, 2011
    Date of Patent: September 22, 2015
    Inventors: Robert M. Winslow, Nancy Jo Winslow, Kim Vandegriff, Ashok Malavalli
  • Patent number: 9121021
    Abstract: Methods for the treatment of a disorder characterized by excessive proliferation and/or lipid content of sebocytes are disclosed. In one embodiment of the invention, the method comprises administering to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition comprising a small molecule inhibitor targeted to galectin-12 or a nucleic acid-based inhibitor targeted to galectin-12 and a pharmaceutically acceptable carrier, wherein said inhibitor is a non-naturally occurring molecule and administration of said inhibitor produces a decrease in the proliferation and/or lipid content of the sebocytes. Methods for decreasing sebaceous gland size, inhibiting sebocyte proliferation, and/or inhibiting sebocyte lipid content are also disclosed.
    Type: Grant
    Filed: November 6, 2014
    Date of Patent: September 1, 2015
    Assignee: ACADEMIA SINICA
    Inventors: Fu-Tong Liu, Wei-Chen Hsieh, Ri-Yao Yang
  • Patent number: 9066966
    Abstract: A method for preventing or treating cardiomyopathy due to energy failure in a subject in need thereof is provided. The method comprises administering to the subject a therapeutically effective amount of a vector which comprises a nucleic acid sequence encoding a gene that can reverse energy failure. An exemplary cardiomyopathy is that which is associated with Friedreich ataxia and an exemplary nucleic acid sequence comprises a nucleic acid that encodes frataxin (FXN).
    Type: Grant
    Filed: February 1, 2013
    Date of Patent: June 30, 2015
    Assignees: Institut National de la Sante et de la Recherche Medicale (INSERM), CNRS (Centre National de la Recherche Scientifique), Universite de Strasbourg, Cornell University, Universite Paris-Sud XI, Assistance Publique-Hopitaux de Paris (APHP)
    Inventors: Helene Monique Puccio, Patrick Aubourg, Ronald G. Crystal, Pierre Bougneres
  • Patent number: 9045542
    Abstract: The present invention includes compositions and methods for enhancing Th1/Th17 cell responses and decreasing Th2 cell responses. In various embodiments the present invention describes activation of human dendritic cells and enhancement of antigen-specific T cell responses in a Dectin-1-expressing human dendritic cells comprising an anti-Dectin-1-specific antibody or fragment thereof fused with one or more antigens. TLR2 ligands may also be included to enhance the activation and for enhancement of T-cell responses. Further, the invention also includes methods based on the compositions described herein for the treatment of allergy, and asthma.
    Type: Grant
    Filed: August 28, 2012
    Date of Patent: June 2, 2015
    Assignee: Baylor Research Institute
    Inventors: SangKon Oh, Jacques F. Banchereau, Gerard Zurawski, Hideki Ueno, Ling Ni
  • Publication number: 20150139999
    Abstract: Described are compositions and methods useful for modulating the immune system of a subject. Also included are diagnostic methods for monitoring an immunologic condition. In particular the invention relates to antagonists of interferon proteins and associated methods of use as well as methods to develop neutralizing antibodies against IFN antagonists to treat viral infections.
    Type: Application
    Filed: June 5, 2014
    Publication date: May 21, 2015
    Inventors: Sergei V. Kotenko, Geoffrey L. Smith
  • Patent number: 9034817
    Abstract: Described are polypeptide dimers comprising two soluble gp130 molecules wherein each of said molecules is fused to an Fc domain of an IgG1 protein and wherein the hinge region of the Fc domain is modified resulting in advantageous properties of the dimer. In a particularly preferred embodiment, the hinge region comprises the amino acid sequence motif Ala234-Glu235-Gly236-Ala237. Moreover, a pharmaceutical composition containing said dimer and various medical uses are described.
    Type: Grant
    Filed: December 17, 2013
    Date of Patent: May 19, 2015
    Assignee: CONARIS RESEARCH INSTITUTE AG
    Inventors: Georg H. Wätzig, Dirk Seegert
  • Publication number: 20150133530
    Abstract: The present invention provides AAV capsid proteins comprising modification of one or a combination of the surface-exposed lysine, serine, threonine and/or tyrosine residues in the VP3 region. Also provided are rAAV virions comprising the AAV capsid proteins of the present invention, as well as nucleic acid molecules and rAAV vectors encoding the AAV capsid proteins of the present invention. Advantageously, the rAAV vectors and virions of the present invention have improved efficiency in transduction of a variety of cells, tissues and organs of interest, when compared to wild-type rAAV vectors and virions.
    Type: Application
    Filed: May 15, 2013
    Publication date: May 14, 2015
    Applicant: University of Florida Research Foundation, Inc.
    Inventors: Arun Srivastava, George Vladimirovich Aslanidi, Kim M. Van Vliet, Mavis Agbandje-Mckenna
  • Publication number: 20150132286
    Abstract: The present invention provides a method for diagnosing and detecting diseases associated with pancreas. The present invention provides one or more proteins or fragments thereof, peptides or nucleic acid molecules differentially expressed in pancreatic diseases (PCAT) and antibodies binds to PCAT. The present invention provides that PCAT is used as targets for screening agents that modulates the PCAT activities. Further, the present invention provides methods for treating diseases associated with pancreas.
    Type: Application
    Filed: September 18, 2014
    Publication date: May 14, 2015
    Inventors: Bruno DOMON, Ian MCCAFFREY, Vaibhav NARAYAN, Scott PATTERSON
  • Patent number: 9029320
    Abstract: Formulations and methods for weight loss and body contouring are disclosed. An illustrative formulation comprises human chorionic gonadotrophin (hCG) and resveratrol. An illustrative method for weight loss and body contouring comprises administering hCG and resveratrol sublingually.
    Type: Grant
    Filed: August 26, 2013
    Date of Patent: May 12, 2015
    Assignee: Red Mountain Med Spa, LLC
    Inventors: Mark Bentz, Suzanne Bentz, Riccardo Roscetti, M. Socorro Parra Arenas
  • Patent number: 9029331
    Abstract: The invention relates to methods of preparing and purifying conjugates between Granulocyte Colony Stimulating Factor and PEG moieties. The conjugates are linked via an intact glycosyl linking group that is interposed between and covalently attached to the peptide and the modifying group. The conjugates are purified using various chromatography methods.
    Type: Grant
    Filed: January 10, 2006
    Date of Patent: May 12, 2015
    Assignee: Novo Nordisk A/S
    Inventors: Shawn DeFrees, Henrik Clausen, David A. Zopf, Caryn Bowe, Susann Taudte, Michael Felo, Walter S. Willett
  • Patent number: 9029315
    Abstract: The subject invention provides novel soluble PD-1 (sPD-1) proteins, nucleic acids, and fusion constructs thereof, for enhancing humoral and cell-mediated immunity of a subject. Also provided are therapeutic compositions comprising the sPD-1 proteins, nucleic acids, and fusion constructs of the subject invention. In a preferred embodiment, the therapeutic composition is formulated as a vaccine composition. Advantageously, the sPD-1 proteins, nucleic acids, and therapeutic compositions provide protective immunity against pathogenic infection including HIV infection. In addition, the subject invention can be used in the prevention and/or treatment of tumor or cancer.
    Type: Grant
    Filed: November 11, 2011
    Date of Patent: May 12, 2015
    Assignee: The University of Hong Kong
    Inventors: Zhiwei Chen, Jingying Zhou
  • Patent number: 9029328
    Abstract: The invention provides methods and compositions for reducing, preventing or reversing cardio toxicity side effects associated with certain therapeutic agents. The invention also provides methods and compositions for treating heart dysfunction including heart failure, and for reversing the effects of myocardial infarction. The various aspects of the invention involve the use of ligand dimers, such as neuregulin dimers, that selectively induce the dimerization of certain EGF receptors in cardiac tissue.
    Type: Grant
    Filed: March 24, 2011
    Date of Patent: May 12, 2015
    Assignees: The Brigham and Women's Hospital, Inc., Massachusetts Institute of Technology
    Inventors: Steven M. Jay, Linda G. Griffith, Richard T. Lee
  • Publication number: 20150126459
    Abstract: The invention relates to the treatment of a hypersensitivity immune response caused by a non-profilin allergen of a profilin-containing plant material (e.g. grass or tree pollen) by bystander suppression with a plant profilin (e.g. Phl p 12, Bet v 2, or Ole e 2) or a variant thereof. Also the invention features a particular variant of Phl p 12 with two of its cysteine residues replaced with another amino acid to increase its pharmaceutical properties.
    Type: Application
    Filed: April 16, 2013
    Publication date: May 7, 2015
    Inventors: Kaare Lund, Jens Brimnes, Helene Henmar, Hans-Henrik Ipsen, Lise Lund Mærkedahl, Gitte Nordskov Hansen, Rafael Ignacio Monsalve Clemente
  • Publication number: 20150126452
    Abstract: The present invention relates to a method for assembling (monomeric or oligomeric) proteins and peptide structures to multimeric protein or peptide structures. The present invention also provides a method for preparing peptide based polymers by crosslinking such multimeric proteins or peptides obtainable according to the inventive method and their use as polymers, for amphiphilic applications, as protein based detergents, for forming artificial organelles, etc. Disclosed are furthermore novel protein or peptide structures, nucleic acids encoding same and cloning and expression vectors suitable for carrying out the inventive method for assembling multimeric proteins or peptides.
    Type: Application
    Filed: May 28, 2013
    Publication date: May 7, 2015
    Inventors: Stefan Schiller, Matthias Huber
  • Patent number: 9023798
    Abstract: The present invention provides compositions and methods for providing factor replacement therapy. In particular, the present invention provides replacement therapy for subjects suffering from cystinosis.
    Type: Grant
    Filed: July 23, 2010
    Date of Patent: May 5, 2015
    Assignee: The Regents of the University of Michigan
    Inventors: Jess Thoene, Jeffrey Innis
  • Patent number: 9023799
    Abstract: A method to treat the chronic stage of heart injury after ischemia or reperfusion by administering Midkine to a subject in need of such treatment is described.
    Type: Grant
    Filed: December 6, 2005
    Date of Patent: May 5, 2015
    Assignee: Cellmid Limited
    Inventors: Mitsuru Horiba, Itsuo Kodama, Takashi Muramatsu, Kenji Kadomatsu
  • Publication number: 20150119333
    Abstract: The invention provides Galectin-3 binding protein (Gal-3BP, BTBD17B) polypeptide sequences and compositions that include Gal-3BP polypeptide sequences, and methods of using Gal-3BP polypeptide sequences, including modified forms and wild type (native) forms of Gal-3BP polypeptide, such as in treatment, diagnostic, detection and prognostic methods.
    Type: Application
    Filed: September 18, 2013
    Publication date: April 30, 2015
    Applicant: La Jolla Institute for Allergy and Immunology
    Inventors: Klaus LEY, Christian GLEISSNER
  • Publication number: 20150119339
    Abstract: A method of care is described that includes administering an effective amount of ?-hydroxy-?-methylbutyrate (HMB) to an adult or elderly patient to decrease the risk of an adverse health event during or subsequent to hospitalization of the patient.
    Type: Application
    Filed: June 10, 2013
    Publication date: April 30, 2015
    Applicant: ABBOTT LABORATORIES
    Inventors: Menghua Luo, Jeffrey L. Nelson, Anne C. Voss, Owen J. Kelly, Geraldine E. Baggs, Min Tian, Jamie Partridge
  • Publication number: 20150111822
    Abstract: There are provided compositions and methods for modulating stem cell division, in particular, division symmetry. It has been demonstrated that Wnt7a polypeptide fragments promoting symmetrical expansion of stem cells. The compositions and methods of the invention are useful, for example, in modulating stem cell division symmetry in vitro, ex vivo, and in vivo, in replenishing and expanding the stem cell pool, and in promoting the formation, maintenance, repair and regeneration of tissue.
    Type: Application
    Filed: September 14, 2012
    Publication date: April 23, 2015
    Inventors: Michael A. Rudnicki, Conrad Florian Bentzinger, Radoslav Zinoviev
  • Publication number: 20150110778
    Abstract: Disclosed herein are compositions and methods for the treatment and/or protection of airway cells and/or tissue from damage due to injury to the lungs or complications of underlying respiratory, cardiovascular or infectious diseases, or any combination thereof.
    Type: Application
    Filed: September 6, 2012
    Publication date: April 23, 2015
    Applicant: Rutgers, the State University of New Jersery
    Inventors: Jianjie Ma, Noah Weisleder
  • Patent number: 9012409
    Abstract: B7-H5 costimulatory polypeptides, nucleic acids encoding such polypeptides, and methods for using the polypeptides and nucleic acids to enhance a T cell response are provided herein.
    Type: Grant
    Filed: March 28, 2013
    Date of Patent: April 21, 2015
    Assignee: Mayo Foundation for Medical Education and Research
    Inventor: Lieping Chen
  • Patent number: 9012401
    Abstract: The invention relates to novel biosynthetic growth factor mutants which exhibit improved biological activity.
    Type: Grant
    Filed: March 3, 2006
    Date of Patent: April 21, 2015
    Assignees: Biopharm Gesellschaft zur biotechnolgischen Entwicklung von Pharmaka mbH, Charite-Universitatsmedizin Berlin, Freie Universitat Berlin
    Inventors: Stefan Mundlos, Petra Knaus, Jens Pohl, Michael Kruse, Frank Plöger
  • Patent number: 9011853
    Abstract: Fusion proteins containing B7-H4 polypeptides are disclosed. The B7-H4 fusion proteins can include full-length B7-H4 polypeptides, or can contain a fragment of a full-length B7-H4 polypeptide, including some or all of the extracellular domain of the B7-H4 polypeptide. Methods for using the fusion proteins to downregulate T cell activation and for the treatment of inflammatory and autoimmune diseases and disorders are also disclosed. The B7-H4 fusion proteins are useful for treating inflammation by inhibiting or reducing differentiation, proliferation, activity, and/or cytokine production and/or secretion by ThI, ThI 7, Th22, and/or other cells that secrete, or cause other cells to secrete, inflammatory molecules, including, but not limited to, IL-1?, TNF-?, TGF-beta, IFN-?, IL-17, IL-6, IL-23, IL-22, IL-21, and MMPs; or enhancing IL-IO secretion by Tregs, increasing the differentiation of Tregs, increasing the number of Tregs, or combinations thereof.
    Type: Grant
    Filed: August 31, 2010
    Date of Patent: April 21, 2015
    Assignee: Amplimmune, Inc.
    Inventors: Solomon Langermann, Linda Liu, Joseph R. Podojil, Stephen D. Miller, Shannon Marshall
  • Patent number: 9012408
    Abstract: The invention relates to methods and compositions for treating undifferentiated arthritis (UA) and/or preventing the development of rheumatoid arthritis (RA) in subjects with UA by administering to a subject in need thereof an effective amount of soluble CTLA4 molecule.
    Type: Grant
    Filed: March 27, 2013
    Date of Patent: April 21, 2015
    Assignee: Bristol-Myers Squibb Company
    Inventors: George Vratsanos, Jean-Claude Becker, Michael Corbo
  • Publication number: 20150105333
    Abstract: Provided herein are methods or reactivating a latent Human Immunodeficiency Virus (HIV) infection in a cell. The methods comprise modulating a level of NF-?B activity in the cell by contacting the cell with an agent that produces a transient first increase in the level of NF-?B activity without a second delayed increase in NF-?B activity. Optionally, a second agent is used to prime the reactivation. Also provided herein is an isolated Massilia bacterium or population thereof capable of producing a HIV-1 reactivating factor (HRF). Also provided are methods of culturing the Massilia bacteria. Further provided are methods of reactivating a latent Human Immunodeficiency Virus-1 (HIV-1) infection in a subject comprising administering to the subject a HIV-1 reactivating factor produced by Massilia bacteria, optionally with a priming agent.
    Type: Application
    Filed: October 17, 2014
    Publication date: April 16, 2015
    Inventors: Olaf Kutsch, Michael Niederweis, Frank Wolschendorf, Alexandra Duverger, Frederic Wagner